MedCity News July 11, 2024
Ipsen has acquired global rights to a Foreseen Biotechnology antibody drug conjugate developed for an undisclosed cancer target. This is Ipsen’s second ADC deal in three months, following its acquisition of rights to a ROR1-targeting ADC from Sutro Biophrama.
Ipsen is spreading its bets in a fast-growing and competitive area of cancer drug research, striking a deal for a novel Foreseen Biotechnology antibody drug conjugate (ADC) that’s on track for its first test in humans.
Paris-based Ipsen is getting global rights Foreseen’s FS001, which the companies say targets a novel tumor-associated antigen overexpressed in many solid tumors. They aren’t saying what that target is, other than to describe it as playing a critical role in tumor proliferation and metastasis. The...
Today's Sponsors
Today's Sponsor